Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893253 | 0.80 | NPC1 (0.71) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL166484 | 0.79 | LMNA (0.82) | KMT2AMEN1CA2LMNANPC1 | |
| Hydrochloric Acid SCHEMBL27843329 | 0.78 | LMNA (0.80) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL1393086 | 0.77 | LMNA (1.00) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL21768049 | 0.76 | LMNA (0.76) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL18031536 | 0.74 | LMNA (0.74) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL11626590 | 0.74 | POLB (0.74) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL95175 | 0.74 | LMNA (0.74) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL13102332 | 0.74 | RAB9A (0.74) | KMT2AMEN1CA2LMNANPC1 | |
| SCHEMBL11625676 | 0.74 | LMNA (0.74) | KMT2AMEN1CA2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | KMT2A 4463/4885MEN1 3669/4885CA2 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.